Abstract:Abstract 4475 Imatinib mesylate is a selective tyrosine kinase inhibitor targeting BCR-ABL fusion protein. In the therapy of either interferon refractory or newly diagnosed chronic myeloid leukemia (CML), imatinib significantly improved the prognosis of the disease, albeit with typically mild to moderate adverse effects. In recent years, increasing attention has been focused on the skin hypopigmentation developed after the initiation of imatinib therapy, especially in Asian countries such as India, with the incidence between 33% and 85%, though sparsely reported in western countries. The inhibition of c-kit by imatinib may be a possible explanation, but the exact mechanism for this hypopigmentation caused by imatinib and its potential risk in patients is poorly understood. Here we report our clinical observation of this side effect of imatinib therapy among Chinese CML patients in our institution, as well as a brief in vitro study aiming to investigate the mechanism of the hypopigmentory effect and evaluate its potential risk. Among 116 patients who took imatinib for CML therapy, 90 of them (77.6%) had reported to develop generalized hypopigmentation or whitening in the skin. This side effect usually developed within 3 months after initiation of imatinib, persistent during the therapy, and reversible upon imatinib discontinuation, according to our interviews and observation. More interestingly, in three of these CML patients who originally had vitiligo, the cosmetic appearance seemed to be improved during imatinib therapy due to the whitening effect on normal pigmented skin areas. To further confirm and understand this side effect, we examined the impact of imatinib on cultured normal human melanocytes derived from the foreskins of healthy Chinese adults. Melanocytes were treat with various concentrations of imatinib (1~16 μ M) for different periods of time (1~7 days). Cell proliferation and apoptosis were detected by cell counting kit-8 and flow cytometric assay, respectively. The melanogenic activity of the melanocytes was detected by melanin content assay and tyrosinase activity assay. Moreover, the role of stem cell factor (SCF) and its receptor c-kit in imatinib induced hypopigmentation were investigated. We found that imatinib not only concentration-dependently inhibited melanocyte proliferation in vitro (IC50=6.23 μ M), but also resulted in massive melanocyte apoptosis at concentrations higher than 8 μ M (P Disclosures: No relevant conflicts of interest to declare.

Impaired Wound Healing with Imatinib Mesylate Therapy

Effect of imatinib on oral wound healing after extraction: A rare case report

Imatinib mesylate-induced lichenoid drug eruption

Imatinib mesylate-induced acute hepatotoxicity

Lichenoid drug eruption associated with imatinib mesylate therapy

Imatinib Therapy of Chronic Myeloid Leukemia Significantly Reduces Carnitine Cell Intake, Resulting in Adverse Events

Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report

Imatinib-induced dermatomyositis sine dermatitis - a rare case report

The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure

Acute ischemic intestinal necrosis as a rare side effect of nilotinib

Development of Sunitinib in the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumors

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Imatinib Mesylate Alone for Refractory Advanced Gastrointestinal Stromal Tumor

Lichenoid Drug Eruption Caused by Imatinib Mesylate in a Chinese Patient with Gastrointestinal Stromal Tumor.

Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation in Chinese Patients with Chronic Myelogenous Leukemia.

Imatinib Impairs CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168 in Vitro

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors

The blue palate-A case series of imatinib-related oral pigmentation and literature review